Graphite Bio Inc
NASDAQ:LENZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clearwater Paper Corp
NYSE:CLW
|
US |
|
C
|
Componenta Oyj
OMXH:CTH1V
|
FI |
Graphite Bio Inc
Short-Term Debt
Graphite Bio Inc
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Graphite Bio Inc
NASDAQ:LENZ
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Short-Term Debt
$2.5B
|
CAGR 3-Years
1 257%
|
CAGR 5-Years
136%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Short-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Graphite Bio Inc
Glance View
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
See Also
What is Graphite Bio Inc's Short-Term Debt?
Short-Term Debt
0
USD
Based on the financial report for Dec 31, 2025, Graphite Bio Inc's Short-Term Debt amounts to 0 USD.
